摘要
目的观察盐酸安罗替尼联合替吉奥治疗老年进展期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取30例经病理组织学和(或)细胞学检查确诊的表皮生长因子(EGFR)突变阴性老年进展期NSCLC患者为研究对象,予盐酸安罗替尼胶囊联合替吉奥胶囊治疗,连续口服14天,停药7天,21天为1个周期,直至疾病进展或出现不可耐受的不良反应。根据实体瘤疗效评价标准进行疗效评价。结果30例患者中,2例患者失访,其余28例患者中,部分缓解9例,疾病稳定15例,疾病进展4例,客观缓解率为32.1%,疾病控制率为85.7%,中位无进展生存期为6.5个月(95%CI:5.8~7.2个月),中位总生存期为10.5个月(95%CI:8.9~12.1个月)。最常见的不良反应包括骨髓抑制、恶心呕吐、乏力、高血压、手足综合征、皮肤黏膜反应、肝功能异常、肾功能异常、蛋白尿以及腹泻等,所有不良反应经对症治疗后均可缓解。结论盐酸安罗替尼联合替吉奥治疗老年进展期NSCLC患者具有较好的临床疗效,且不良反应可耐受。
Objective To observe the efficacy and safety of anlotinib hydrochloride combined S-1 in elderly patients with advanced progressive non-small cell lung cancer(NSCLC).Method A total of 30 elderly patients with histological-ly and(or)cytologically confirmed epidermal growth factor receptor(EGFR)mutation-negative advanced progressive NSCLC were selected,all patients received anlotinib hydrochloride and S-1 for 14 days with 7 days discontinuation as one cycle(21 days)until disease progression or treatment intolerance.Efficacy was evaluated according to response eval-uation criteria in solid tumor.Result Two patients were lost to follow-up in 30 patients.Among the evaluable 28 pa-tients,9 patients achieved partial response(PR),15 had stable disease(SD)and 4 patients had progressive disease(PD).The objective response rate(ORR)was 32.1%and the disease control rate(DCR)was 85.7%.The median progression free survival(mPFS)and the median overall survival(mOS)were 6.5 months(95%CI:5.8-7.2)and 10.5 months(95%CI:8.9-12.1),respectively.The most common adverse events included bone marrow suppression,nausea and vomiting,fa-tigue,hypertension,hand-foot syndrome,skin and mucous membrane reaction,abnormal liver function,abnormal renal function,proteinuria and diarrhea,all relieved after symptomatic treatment.Conclusion Anlotinib hydrochloride com-bined S-1 has significant therapeutic efficacy in elderly patients with advanced progressive NSCLC and well-tolerated ad-verse events.
作者
王建芳
纪蓉
孙彩萍
陈遐林
WANG Jianfang;JI Rong;SUN Caiping;CHEN Xialin(Department of Oncology,Shaoxing People’s Hospital,Shaoxing 312000,Zhejiang,China;Department of Radiotherapy,Shaoxing Second Hospital,Shaoxing 312000,Zhejiang,China)
出处
《癌症进展》
2022年第3期242-245,共4页
Oncology Progress
基金
浙江省医学会临床科研基金项目(2019ZYC-A47)
绍兴市科技局公益性技术应用研究项目(2018C30096)。
关键词
盐酸安罗替尼
替吉奥
非小细胞肺癌
老年
anlotinib hydrochloride
S-1
non-small cell lung cancer
elderly